Data Safety Monitoring Board Guidance To Provide Rules For Halting Trials
This article was originally published in The Gray Sheet
Executive Summary
FDA's draft guidance on data safety monitoring boards (DSMBs) will address when clinical trials should be stopped for safety or efficacy reasons.
You may also be interested in...
Risk-Based Approach To Clinical AE Reporting Needed – Medtronic’s Westrum
Clinical trial sponsors are limited in their ability to facilitate compliance with institutional review boards, even though investigators often lack thorough grounding in IRB policies, according to Medtronic Director of Clinical Affairs Barbara Westrum
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.